End-OSA 
Endobarrier in Obstructive Sleep Apnoea Study
 

Background

Repeated episodes of complete or partial blockage of upper airway during sleep constitute Obstructive sleep apnoea (OSA), which is associated with obesity and Type 2 Diabetes Mellitus. Continuous positive airway pressure (CPAP) machine used overnight to treat OSA is not comfortable to wear over the face. Any weight loss achieved by diet, lifestyle and medications is useful but for some people it is insufficient for maximum health benefit. Bariatric surgery does help in loosing significant weight but it is expensive and not without significant complications. In the quest for new treatments to address this problem, endobarrier seems to be effective in clinical trials improving diabetes and obesity, or ‘diabesity’. Now, with End-OSA trial we are aiming to check its effectiveness on OSA in an NHS setting.
 

What is the End-OSA study?

End-OSA study is a single-centre clinical trial based at City Hospital(Sandwell and West Birmingham Hospitals NHS Trust), initiated and funded by ABCD. This is a clinical investigational study of a medical device called Endobarrier running over a period of 2 years, which seeks to answer the following questions:

• Does the weight loss achieved with endobarrier improve obstructive sleep apnoea to such an extent that they no longer  require CPAP treatment?
• Whether there is any improvement in OSA symptoms and any reductions in CPAP pressures due to endobarrier?
• To assess the extent of improvement in diabetes control, cardiovascular risk factors and fatty liver disease following endobarrier insertion
 

 Below is the flowchart of the study schedule -
 

Study leads

• Dr Bob Ryder – Chief Investigator whole study & Principal Investigator (City Hospital, Birmingham site)

• Dr Mahender Yadagiri – ABCD Research Fellow

• Dr Piya Sen Gupta - ABCD Research  Fellow

Working to support high quality diabetes care in the UK